Japan's Ministry of Health has approved Sanofi's Sarclisa subcutaneous (SC) formulation for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval is based on the IRAKLIA phase 3 study showing the SC form is as effective as the intravenous version, with fewer infusion reactions and added convenience. Sarclisa SC can be administered manually or via an on-body injector (OBI), potentially the first anticancer treatment in Japan using this technology. This approval addresses growing multiple myeloma cases in Japan and offers patients a less burdensome treatment option.
DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF ...
COUR Pharma secured $50 million in a Series B funding round led by Lumira Ventures and Roche Venture Fund, with new investment from Sanofi. The funds will support clinical trials of CNP-103, a novel immune tolerance therapy targeting type 1 diabetes ...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
Sanofi reported robust sales growth in Q1 2026, with Sarclisa sales rising 30.1% to $193.21 million and Dupixent sales increasing 30.8% to $4.85 billion. The company is expanding Sarclisa's reach with an on-body injector to compete in the multiple my...
